“Nasal Vaccine Set to Take on Flu Shot”

Return to Vaccination News Home Page

Subscribe to the Vaccination NewsLetter

View past & current Scandals (columns by Sandy Mintz)

Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.

The Food and Drug Administration is expected to approve a nasal influenza vaccine by the end of June, which would make it available for the next flu season. The vaccine is called FluMist, and manufacturer MedImmune says that it could increase the number of people seeking immunization since many fear needles. The nasal vaccine uses a diluted live virus instead of the killed virus of the injectable vaccine; and because that weakened virus could be a risk to those with weakened immune systems, FluMist will probably only be approved for healthy people between five and 49 years of age. However, this excludes the groups most likely to get vaccinated for flu, and while MedImmune intends to seek further approvals, doing so will probably take a couple of years. FluMist's price is expected to be at least $30 per dose, which is more than double that of a flu shot, and the company says it can only produce 6 million doses at most for the first flu season due to manufacturing limitations. MedImmune adds that most of the doses will be given by medical personnel, and it is not yet clear whether the nasal vaccine can be self-administered.

Return to Vaccination News Home Page

DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.